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Abstract
The defects in the mitochondrial genome are associated with different pathologies, 
including atherosclerosis. It is generally believed that atherosclerosis leads to premature 
cell senescence, but there is increasing evidence that cell senescence, the biomarker of 
which is the mutational load of mitochondrial genome, is itself a mechanistic factor of 
atherogenesis. The basic scientific problem addressed is an examination of functional 
consequences of mitochondrial DNA (mtDNA) damage based on the analysis of variabil-
ity of mitochondrial genome. The paper is devoted to identification of genetic markers 
of mtDNA mutation burden, molecular and cellular markers of disorders in functional 
properties of cells arising from mutations in the mitochondrial genome, and identifica-
tion of combinations of genetic markers that lead to violation of functional properties 
of human monocyte-macrophages. New data are presented, which resulted from whole 
genome sequencing of mtDNA from atherosclerotic lesions of arterial intima, the analy-
sis of the relationship of mtDNA damage with the changes in cellular composition of 
arterial intima and expression of apoptosis- and inflammation-related genes, retrieving 
the data on mitochondrial genome variability in patients with atherosclerosis, and the 
study of functional activity of human blood monocytes differing substantially by the 
degree of mtDNA mutation burden.
Keywords: atherosclerosis, mitochondrial DNA, mitochondrial dysfunction, mutations, 
predisposition
1. Introduction
The defects in the mitochondrial genome are often associated with various human patholo-
gies. There is the evidence that such a relationship can be in the case of atherosclerosis. The 
nature and the mechanisms of this association remain unclear. The basic scientific problem, 
to which the given chapter is aimed, is the study of functional consequences of mtDNA dam-
age based on the analysis of variability of the mitochondrial genome. The disclosure of those 
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associations will provide new knowledge on atherogenesis as an age-related degenerative 
pathological process and will create a basis for development of new approaches to the diag-
nosis, prevention, and treatment of atherosclerosis.
Chronic age-related degenerative diseases account for the major share of mortality in soci-
ety. The most frequent pathology is atherosclerosis, which is classified as a typical disease of 
aging, and its prevalence in the elderly reaches 100%. It is generally believed that atheroscle-
rosis leads to premature biological aging of cells, but there exists also the increasing evidence 
that cell aging, one of the indicators of which is the mutational load of mitochondrial genome, 
is a mechanistic factor of atherogenesis. In such a case, the association of mitochondrial DNA 
(mtDNA) variability with the disturbances in the functional properties of the artery wall cells 
participating in atherogenesis remains poorly understood. The results of the study of the 
association of mtDNA damage and functional properties of cells based on the analysis of the 
mitochondrial genome variability will make it possible to establish the features and patterns 
of the pathology of vascular aging and to justify the assumption that the prevention of acceler-
ated cell aging is a therapeutic target in atherosclerosis.
Mammalian cells contain dozens, hundreds, and even thousands of mtDNA copies. It was 
previously assumed that all mtDNA molecules are identical at birth [1, 2]. However, later stud-
ies have shown that about 25% of healthy people inherit a mixture of wild-type and variant 
mtDNA (the phenomenon of heteroplasmy) and the latter may imply potentially pathogenic 
variants in the coding region of mtDNA [3, 4]. The mitochondrial genome is characterized by 
exaggerated instability, with an estimated mutation rate of at least 5–15 times higher than that 
of the nuclear genome. This is partly a result of proximity to the electron transport chain, which 
is the main intracellular source of free oxygen radicals, and partly due to relatively limited pro-
tection and reparation of mtDNA mechanisms [5]. The high frequency of mutations determines 
the high level of mtDNA variability, as well as the appearance of somatic mutations of mtDNA 
with the aging of human organism [6]. The proportion of mutant copies of mtDNA carrying 
both inherited and somatic mutations may be changed during lifetime due to unequal separa-
tion of mitochondrial genotypes during cytokinesis in dividing cells (vegetative segregation) or 
in nondividing cells during mtDNA replication. An increase in the degree of heteroplasmy rep-
resents a kind of “clonal expansion” of low-level inherited variants, which occurs due to pref-
erential replication of mtDNA carrying certain types of mutations [7]. Exceeding the critical 
threshold level of the degree of heteroplasmy of pathogenic mutations in the cell is manifested 
by biochemical defects in the mitochondrial respiratory chain [8]. The high level of mtDNA 
mutations manifests itself in the form of multi-system mitochondrial diseases [9] and degenera-
tive age-related diseases and undoubtedly contributes to biological aging processes [10].
The basic scientific problem addressed by this chapter is an examination of functional con-
sequences of mitochondrial DNA (mtDNA) damage based on the analysis of variability of 
mitochondrial genome. The described results are devoted to identification of genetic markers 
of mutational load of mitochondrial genome, molecular and cellular mechanisms of disorders 
in functional properties of cells arising from mutations in the mitochondrial genome, and 
identification of combinations of genetic markers that lead to violation of functional proper-
ties of human monocyte-macrophages.
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2. The markers of mitochondrial DNA mutation load in atherosclerotic 
lesions
It has been shown earlier that several mutations of mitochondrial genome have significantly 
higher prevalence and mean value in lipofibrous plaques as compared to non-atherosclerotic 
intima and therefore are associated with atherosclerosis [11–13].
In continuation of the above studies, the samples of human thoracic aorta (32 samples, 19 
men, 13 women aged 53–78 years old) were taken at autopsy performed within 6–16 h after 
sudden death. After macroscopic identification of unaffected and atherosclerotic areas of 
the aorta (initial lesions, fatty streaks, lipofibrous and fibrous plaques), autopsy aortic sam-
ples (2 × 2 cm, 4–9 sites per autopsy sample) were excised for further studies. In addition, 
five aortas were subjected to complete morphological mapping, that is, from whole sam-
ples approximately 8 × 12 cm in size, 25–56 sites differing by the degree of atherosclerotic 
lesion were obtained. The total of 297 samples was obtained. Histological and immunocyto-
chemical analysis of the samples was carried out; DNA and RNA were isolated from aortic 
intima. For the analysis of mtDNA mutations, the pyrosequencing technology was used.
The analysis of heteroplasmy of mitochondrial genome of cells from unaffected and athero-
sclerotic regions of aortic intima was performed for 42 mutations previously known from 
the MITOMAP database (m.652delG, m.652insG, m. 716T>G, m. 750A>G, m.961insC, m. 
961delC, M.1555A>G, m.3256C>T, m.3258T>C, m.3271T>C, m.3280A>G, m.3285C>T, m. 
3316G>A, m.3336T>C, m. 5132insAA, m.5178C>A, m.5540G>A, m.5692T>C, m.5814T> 
C, m.6489C>A, m.8362T>G, m.8363G>A, m.8993T>G, M.8993T>C, m.9379G>A, m.9480del15, m. 
9537insC, m.12315G>A, m.13513G>A, m.14459G>A, m.14482C>G, m.14482C>A, 
M.14484T>C, m.14487T>C, m.14709T>C, m.14846G>A, m.15059G>A, m.15084G>A, 
m.15452C>A, m.15498del24, m.15723G>A, and m.15762G>A). Thus, most of the mito-
chondrial DNA genes encoding enzymes (9 of 13) were covered, except for the MT-CO2 
(subunit II of cytochrome oxidase C), MT-ND3 (subunit 3 of dihydronicotinamide ade-
nine dinucleotide (NADH) dehydrogenase), and MT-ND4L and MT-ND4 (subunits 4L 
and 4 of NADH dehydrogenases). Seven of the 22 genes encoding transport RNA and 
MT-RNR1 gene encoding 12S ribosomal RNA were also covered. Forty examined muta-
tions were heteroplasmic, and two (m.8362T>G and m.8363G>A) were homoplasmic by 
the absence of a mutant allele in atherosclerotic lesions.
The analysis showed that mtDNA variants m.652delG, m.3256C>T, m.12315G>A, m.14459G>A, 
and m.15059G>A were significantly associated with the lipofibrous plaque (p < 0.05), and for 
m.13513G>A and m.14846G>A, the association was significant at the level of p < 0.1. Variants 
m.1555A>G and m.5178C>A were antiatherosclerotic with respect to lipofibrous plaque at 
p < 0.05. In addition to formal statistical analysis, the approach was used where the prevalence 
was used to determine the difference between the indices of heteroplasmy in normal and ath-
erosclerotic lesions in samples obtained from the same donor of autopsy material. As a result, 
11 mtDNA mutations belonging to 8 mitochondrial genes were detected, those encoding 12S 
rRNA; tRNA-Leu (UUR recognition codon); tRNA-Leu (CUN recognition codon); subunits 1, 
2, 5, and 6 of NADH dehydrogenase; and cytochrome B, which were associated with lipofibrous 
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plaques [12–14]. To evaluate the relationship of these mtDNA variants identified as potential 
markers of atherosclerosis, the study was performed on the autopsy material with complete 
morphological and mutational mapping.
It was found that the same mtDNA variants associated with the advanced atheroscle-
rotic lesions are also associated with the initial atherosclerotic lesions (fatty dots and 
fatty streaks). The mutation m.13513G>A was antiatherosclerotic, as it correlated nega-
tively with the degree of atherosclerotic lesion. Mutation m.1555A>G negatively corre-
lated with initial atherosclerotic lesions and lipofibrous plaques (p < 0.05), and mutation 
m.14846G>A—with lipofibrous plaques. Lipofibrous and fibrous plaques tended to pos-
itive correlation with m.652delG mutation at p < 0.1, which being absent in unaffected 
intima and in the initial atherosclerotic lesions. The presence of fibrous plaques positively 
correlated with mtDNA mutations m.3256C>T and m.5178C>A and negatively correlated 
with m.12315G>A [14].
To determine the relationship between the mutational load and the degree of atherosclerotic 
lesion, a linear regression analysis was performed. For each mutation in each aorta, the distri-
bution of the heteroplasmy level was assessed, and interquartile boundaries were determined. 
When estimating the integral mutation burden for 11 mutations, the linear regression model 
reached statistical significance at p < 0.001. Given the sufficient number of degrees of freedom, 
it can be assumed that the degree of atherosclerotic lesion is associated with integral mutation 
burden caused by these mutations at 99.9% probability of error-free prediction. The sensitivity 
and specificity for each of the mutations associated with atherosclerosis were studied. The anal-
ysis was carried out by constructing receiver operating characteristic (ROC) curves with sub-
sequent measurement of the area under the curve, which allowed to describe the explanatory 
properties of genetic markers. For this analysis, the rank values (quartile numbers) of the het-
eroplasmy were summed according to the sign of the beta coefficient obtained in the regression 
analysis. The obtained parameter was assumed as mutation burden. Using this model, sensi-
tivity was 88.2% (p < 0.05, 95% confidence interval from 74.6 to 95.3). The specificity was 77.1% 
(p < 0.05, 95% confidence interval from 70.8 to 87.3). Thus, the integral mutation burden 
assessed by 11 mtDNA variants was associated with 88.2% of the cases of atherosclerotic 
lesions in the morphologically mapped aortas [14].
Further, whole genome sequencing of mtDNA from unaffected and atherosclerotic intima 
of the thoracic aorta, obtained in autopsy (11 cases) within 6–16 h after sudden death, was 
carried out using next-generation sequencing (NGS) technology on the Roche 454 GS Junior 
Titanium platform (Roche Applied Science, USA). The following samples were analyzed: 
unaffected areas of intima (n = 12), initial lesions (n = 14), fatty streaks (n = 15), lipofibrous 
plaques (n = 13), and fibrous plaques (n = 12). The following parameters were achieved: the 
mean reading length, 458 bp; the mean number of readings, 18,734; and the mean number 
of nucleotides read in one sample, 8.65 million bp. The mean percent of mapped readings 
reached 93%. To detect heteroplasmic mutations of mtDNA, sequences with more than 300-
fold coverage of the mitochondrial genome were taken, thus allowing reliable detection of 
mutations with a level of heteroplasmy of at least 1% in the presence of direct and reverse 
readings of the mutant allele.
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It has been established that the mitochondrial genome has a significant individual variability 
and has a much larger number of heteroplasmic mutations than was previously assumed in 
the literature. Most mitochondrial DNA mutations found by whole genome sequencing had a 
low degree of heteroplasmy, but the results of the analysis suggest that there are both general 
and individual variants associated with atherosclerotic lesions [15].
Thus, heteroplasmic mtDNA mutations associated with atherosclerotic lesions were identi-
fied by NGS, and the integral mutation burden of the mitochondrial genome was assessed. 
Ten heteroplasmic mutations of mtDNA were detected that occurred simultaneously in 
different parts of the intima of the aorta (m.368A>G, m.751delA, m.8404T>C, m.8485G>C, 
m.9720delT, m.10663delT, m.14160G>A, m.14207delG, m.16086T>C, and m.16389G>A). The 
level of heteroplasmy of these mutations ranged from 2 to 26%, with more than half of the 
values not exceeding 6%. Among the heteroplasmic mutations found, the majority occurred 
in the coding region, namely, in the mitochondrial 12S-RNA genes, the ATP synthase subunit 
8, the cytochrome oxidase subunits 3 and 4L, and the NADH dehydrogenase subunit 6. One 
mutation was synonymous, and the rest were either deletions or missense mutations. For 
mutations occurring in genes encoding mitochondrial respiratory chain proteins, the levels 
of heteroplasmy did not exceed 15%, while mutations in the hypervariable segment 1 (HVS1) 
and in adjacent noncoding region were characterized by heteroplasmy values of 20–26% [15].
The distribution of mtDNA mutations in various parts of the aortic intima was of a mosaic 
nature, and in some cases, even neighboring parts of the intima were characterized by differ-
ent compositions of heteroplasmic mutations. Unaffected areas of the intima and areas with 
initial lesions (fatty dots) were characterized by an almost complete absence of heteroplasmic 
mutations of mtDNA. In areas with fatty streaks and fibrous and lipofibrous plaques, hetero-
plasmic variants were more common, and the levels of heteroplasmy increased. The high-
est frequency of heteroplasmic mutations was found in lipofibrous plaques, while in areas 
with fatty streaks in close proximity to lipofibrous plaques, an increased frequency of muta-
tions was also observed. The fact of the presence of heteroplasmic deletions, previously not 
described in the literature (m.9720delT, m.10663delT, and m.14207delG in the coding region 
of mtDNA with a level of heteroplasmy up to 15%), was revealed. Because of the reading 
frame shift, the presence of deletions in mtDNA should lead to completely defective syn-
thesis of the mtDNA-encoded proteins, and the level of heteroplasmy at a 15% for deletion 
means that the synthesis of respiratory chain proteins should be reduced by 15%. It should be 
noted that heteroplasmic deletions in the coding region of mtDNA were detected only in fatty 
streaks and lipofibrous plaques. As an example, the distribution of m.9720delT mutation, the 
deletion in the gene encoding cytochrome oxidase subunit 3, may be described: it was found 
with a similar level of heteroplasmy (12–15%) only in areas with fatty streaks and lipofibrous 
plaques, located relatively close to each other [15].
Taking into account the results of pyrosequencing and whole genome sequencing of 
mtDNA, the genes were identified, the damage of which due to point mutations is observed 
in atherosclerotic lesions, and heteroplasmic mtDNA mutations were revealed being asso-
ciated with atherosclerotic lesions: m.368A>G (MT-HV2 gene, hypervariable segment 2), 
M.652delG, m.751delA, m.1555A>G (MT-RNR1 gene, 12S ribosomal RNA), m.3256C>T 
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(MT-TL1 gene, leucine tRNA-recognition codon L-UUA/G), m.5178C>A (MT-ND2 gene, 
subunit 2 of NADH dehydrogenase), m.8404T>C, m.8485G>C (MT-ATP8 gene, subunit 
8 ATP synthase F0), m.9720delT (MT-CO3 gene, subunit III of cytochrome C oxidase), 
m.10663delT (MT-ND4L gene, subunit 4L NADH dehydrogenase), m.12315G>A (MT-TL2 
gene, leucine tRNA-L-CUN recognition codon), m.13513G>A (MT-ND5 gene, subunit 5 
NADH dehydrogenase), m.14160G>A, m.14207delG, m.14459G>A (MT-ND6 gene, sub-
unit 6 NADH dehydrogenase), m.14846G>A (MT-CYB gene, cytochrome b), m.16086T>C 
(MT-HV1 gene, hypervariable segment 1), and m.16389G>A (MT-7SDNA gene, 7S DNA). 
It has been established that the best indicator of the association between mtDNA mutant 
variants and the type of atherosclerotic lesion is integral (total) mutation burden, which 
belongs to the below-described pattern of the first type (bell-shaped relationship with the 
type of atherosclerotic lesion with the maximum at fatty types of lesions—fatty streaks and 
lipofibrous plaques).
3. Cellular composition of atherosclerotic lesions
The use of a set of antibodies covering most of the cells found in the intima made it possible 
to characterize the qualitative and quantitative changes that occur with resident intimal cells 
and cells of hematogenous origin in the same site of the vessel. By the results of immunocy-
tochemical typing, the proportion of smooth muscle cells containing α-actin was determined, 
which was about half of the total cell population in both normal and atherosclerotic intima. 
In the row “unaffected intima—initial lesions—fatty streak—lipofibrous plaque—fibrous 
plaque,” the proportion of cells expressing smooth muscle α-actin was 46.7% (SD = 9.8), 47.2% 
(SD = 7.9), 42.2% (SD = 9.2), 47.0% (SD = 9.9), and 42.4% (SD = 9.0), respectively. Accordingly, 
the rest of the cells (about 50% of the total population) could not be identified with this smooth 
muscle cell marker. About two-thirds of the cells of the muscular-elastic intimal sublayer were 
positively stained with anti-smooth muscle α-actin antibodies, whereas in the proteoglycan 
(subendothelial) intimal sublayer, the percentage of cells containing α-actin was significantly 
lower. Cells of hematogenous origin (lymphocytes and macrophages) were localized only in 
the subendothelial part of the intima in the proteoglycan sublayer. Their proportion increased 
in atherosclerotic lesions and accounted for about 20% of all cells. The percentage of cells 
expressing CD68, the antigen of macrophages, increased with the progression of atheroscle-
rotic lesion: 3.9% (SD = 1.7), 6.1% (SD = 6.3), 13.2% (SD = 3.2), 13.1% (SD = 6.3), and 18.2% 
(SD = 8.8), respectively [16].
Resident intimal cells also expressed antigens uncommon for the typical smooth muscle cells 
of intima media. In areas with advanced atherosclerotic lesions (fatty streaks and lipofibrous 
and fibrous plaques), the cells expressing 2A7 antigen characteristic for pericytes from active 
regions of angiogenesis were present. In unaffected intima, such cells could not be identified. 
The proportion of cells expressing the antigen of activated pericytes (2A7) increased with 
the progression of atherosclerotic lesion in the row “unaffected intima—initial lesions—fatty 
streak—lipofibrous plaque—fibrous plaque”: 0.0% (SD = 0.2), 1.2% (SD = 1.3), 3.0% (SD = 2.8), 
27.0% (SD = 9.9), and 24.0% (SD = 8.6). The maximum proportion of 2A7-positive cells was 
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reached in the lipofibrous plaques. In addition to antibodies against 2A7 antigen, antipericytic 
antibodies 3G5 characteristic for resting pericytes were used. In atherosclerotic lesions, the 
number of cells expressing 3G5 antigen was significantly less than in intact intima. The propor-
tion of cells expressing 3G5 antigen decreased with progression of atherosclerotic lesion in the 
row “unaffected intima—initial lesions—fatty streak—lipofibrous plaque—fibrous plaque”: 
31.3% (SD = 7.0), 16.3% (SD = 4.5), 11.7% (SD = 8.0), 5.0% (SD = 2.8), and 3.9% (SD = 3.6). 
The total number of cells expressing antigens 2A7 and 3G5 remained relatively constant, but 
their ratio varied. The total number of 3G5-positive cells and 2A7-positive cells was about 
30% of the entire cell population in the areas of unaffected intima and atherosclerotic plaques. 
In the initial lesions and fatty streaks, the number of resting and activated pericytes was a 
smaller part. This pattern of expression of two pericyte antigens allows us to assume that 
when atherosclerotic lesions are formed, the functional state of the pericyte-like cells of the 
proteoglycan intima sublayer changes, accompanied by a change in the antigens that they 
express. With double immunocytochemical staining, the CD68 antigen of macrophages was 
expressed not only in cells of hematogenic origin but also in some resident subendothelial 
cells. This suggests that the presence of CD68 antigen is not only a sign of monocytic origin 
of cells but also a marker of their phagocytic activity, which increases when atherosclerotic 
lesions are formed [16].
Thus, smooth muscle cells, macrophages, and lymphocytes are present both in unaffected arte-
rial intima and in the areas of atherosclerotic lesions. In contrast to popular beliefs, no pre-
dominance of monocyte-macrophages among cells inhabiting atherosclerotic lesion has been 
detected. There is a special type of cells expressing pericytic antigens, the number of which con-
stitutes a significant proportion of intimal cells. Pericyte-like cells, together with smooth muscle 
cells, represent the majority of cellular population of subendothelial intima. In the areas of ath-
erosclerotic lesion, the behavior of pericyte-like cells changes—they capture lipids and begin 
to proliferate. This is accompanied by a change in expression of antigens specific for pericytes.
4. Expression of apoptosis-related genes in atherosclerotic lesions
In the aortic intima samples differing by the degree of atherosclerotic lesion, the mRNA 
expression level of several genes associated with apoptosis (CASP3, CASP9, ENO1, NTN1, 
NTN4, and UNC5A) was analyzed. The level of gene expression was evaluated by qPCR.
A monotonous decrease in the expression level of the mRNA of the CASP3 gene depending 
on the degree of atherosclerotic lesion was observed. Maximum CASP3 expression was in 
unaffected intima, the minimum—in fibrous plaques (p = 0.0018). The significant difference 
was found in the expression of the CASP3 gene in fibrous plaque from that in unaffected 
areas (p = 0.041) and initial lesions (p = 0.019), but when compared with fatty streaks and lipo-
fibrous plaques, statistically significant differences were not observed (p = 0.098 and p = 0.061, 
respectively). In a pairwise comparison of all other types of atherosclerotic lesions, there 
was no statistically significant difference in the expression of the mRNA of the CASP3 gene. 
Significant correlation of CASP3 gene expression in unaffected intima and initial lesions was 
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shown (r = 0.643, p = 0.018), as well as in fatty streaks and lipofibrous plaques (r = 0.593, 
p = 0.033). The expression of the CASP9 gene did not practically change in all types of ath-
erosclerotic lesions when compared to unaffected areas, except for fatty streaks, where the 
expression level was almost doubled (p = 0.084, p = 0.030, p = 0.002, and p = 0.046 when com-
pared to the unaffected intima, initial lesions, lipofibrous plaque, and fibrous plaque, respec-
tively). In the samples of fatty streaks and lipofibrous plaques, a significant correlation of the 
expression of the CASP9 gene was noted (r = 0.933, p = 0.031) [16].
It was found that the level of expression of the ENO1 gene increased in areas with severe 
atherosclerotic lesions (lipofibrous and fibrous plaques) at p = 0.021. In the initial types of 
atherosclerotic lesions, the expression of the mRNA of the ENO1 gene did not differ signifi-
cantly from that in the intact intima (p = 0.916 and p = 0.209 for the initial lesions and fatty 
streaks, respectively). When comparing the level of expression in lipofibrous plaques and 
atherosclerotic lesions, no statistically significant differences were found (p = 0.114). However, 
when compared with unaffected areas and initial atherosclerotic lesions, the expression of 
the mRNA of the ENO1 gene significantly increased (p = 0.046 and p = 0.028 for the initial 
lesions and fatty streaks, respectively). The change in the level of expression of the ENO1 
gene in lipofibrous and fibrous plaques did not reach statistical significance (p = 0.080). The 
significant correlation was found for mRNA expression of ENO1 gene in unaffected areas 
and initial lesions (r = 0.618, p = 0.024), unaffected areas and fatty streaks (r = 0.818, p = 0.001), 
initial lesions and fatty streaks (r = 0.655, p = 0.011), initial lesions and lipofibrous plaques (r = 
0.554, p = 0.040), as well as for fatty streaks and lipofibrous plaques (r = 0.629, p = 0.021). It was 
found that the expression level of the mRNA of the NTN1 gene is practically the same in unaf-
fected intima and initial lesions (p = 0.929), and in the fatty streaks it increases insignificantly 
(p = 0.239, p = 0.817 when compared with the unaffected tissue and initial lesions, respectively). 
A sharp decrease in the expression of the NTN1 gene was observed in lipofibrous plaques 
(p = 0.014, p = 0.004, and p = 0.016 when compared with intact unaffected intima, initial lesions, 
and fatty streaks, respectively), as well as in fibrous plaques (p = 0.016, p = 0.006, and p = 0.050 
when compared with unaffected intima, initial lesions, and fatty streaks, respectively). When 
comparing the expression of the mRNA of the NTN1 gene in lipofibrous and fibrous plaques, 
no statistically significant differences were revealed (p = 0.490). A significant correlation of 
the level of expression of the NTN1 gene in unaffected areas and initial lesions (r = 0.888, 
p < 0.001), as well as in unchanged intima and fatty streaks (r = 0.674, p = 0.016), was found.
There were no significant changes in the level of expression of the mRNA of the NTN4 gene 
in all the types of atherosclerotic lesions examined in comparison with unaffected intima. 
The significant correlation of NTN4 gene expression in unaffected intima and initial lesions 
(r = 0.775, p = 0.002) and initial lesions and fatty streaks (r = 0.592, p = 0.033) was revealed. 
The expression profile of the UNC5A gene resembled the changes in the expression level of 
the mRNA of the CAPS9 and NTN1 genes. The highest level of expression was observed in 
the areas of fatty streaks, while in the areas of unaffected intima, initial lesions, and lipofi-
brous plaques, the level of mRNA expression did not practically change. The lowest level of 
expression was observed in fibrous plaques. Statistically significant changes in the expres-
sion of UNC5A gene mRNA were observed in fibrous and lipofibrous plaques (p = 0.046), in 
fibrous plaques and fatty streaks (p = 0.025), as well as in fibrous plaques and initial lesions 
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(p = 0.016). A significant correlation of the expression level of the UNC5A gene in the initial 
lesions and fatty streaks (r = 0.827, p < 0.001), initial lesions and lipofibrous plaques (r = 0.833, 
p < 0.001), fatty streaks and lipofibrous plaques (r = 0.744, p < 0.001), and lipofibrous and 
fibrous plaques (r = 0.961, p = 0.009) was observed.
The presented data of immunocytochemical analysis of changes in cellular composition in 
atherosclerotic lesions can partly explain the patterns of changes in the expression of apop-
tosis-related genes. It can be assumed that if the most significant changes in the cellular com-
position, namely, an increase in the proportion of cells of hematogenic origin, are observed 
in atherosclerotic plaques, the activation of pericyte-like cells is accompanied by correspond-
ing changes in the expression of CASP3, CASP9, ENO1, NTN1 and UNC5A genes. Reduction 
in the expression of CASP3, NTN1, and UNC5A genes may be due to the predominance of 
necrotic processes and cell death in atherosclerotic plaques. Although cell death in athero-
sclerosis occurs in several ways (necrosis, autophagy, and apoptosis), the latter mechanism 
is best described for the processes of cellular aging. Apoptosis is believed to be increased not 
only in senescent vascular cells but also in smooth muscle cells and other types of cells that 
inhabit atherosclerotic plaques. Thus, it is believed that the majority of cell deaths occurring 
in necrotic zones of plaques are associated with apoptosis. However, there are discrepan-
cies such as a decrease in the expression of apoptotic biomarkers in advanced atherosclerotic 
lesions, which is explained by the hypothesis that many apoptotic cells lose their key markers 
of origin, which complicates their precise identification. Nevertheless, we consider the pos-
sibility that the changes in the expression of apoptosis-related genes in atherosclerosis are 
much more dependent on changes in the composition of cells than on loss of markers by aged 
cells.
5. Expression of inflammation-related genes in atherosclerosis
The expression of genes associated with inflammation (TNF-α, CCL18, CD14, IL-1β, CASP1, 
and APAF-1) was measured and analyzed. The results of qPCR analysis showed that both 
in the intact intima of the human aorta and in atherosclerotic lesions, expression of the 
pro-inflammatory cytokine TNF-α and anti-inflammatory cytokine/chemokine CCL18 is 
observed. Quantitative differences are observed between the values obtained for unaffected 
and atherosclerotic regions. In the unaffected intima, the values obtained for both cytokines 
did not differ. However, even in the initial lesion, the expression level of CCL18 was 2.6% 
relatively to the reference housekeeping genes, whereas for TNF-α, it did not reach 2%. In 
advanced fatty lesions, the gap between the values for both cytokines increased. Thus, in 
the fatty streaks, the expression level of CCL18 was approximately 10%, and of TNF-α, it 
was 1.8%; in the lipofibrous plaque, the expression levels were 11.4% and 1.8%, respectively. 
In the fibrous plaque, the level of expression of the studied genes was reduced, but the dif-
ferences for pro-inflammatory and anti-inflammatory cytokines remained, accounting for 
7.4% for CCL18 and 1.1% for TNF-α, respectively. Similar changes in fibrotic plaques can 
be explained by a decrease in cellularity in this type of lesion. The bell-shaped dependence 
of mRNA expression of TNF-α gene on the type of atherosclerotic lesion was found with a 
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maximum attributable to early fatty lesions (in the initial lesions, 2.1-fold increase in expres-
sion, and in fatty streaks and lipofibrous plaques, 1.9-fold increase). The mRNA expression of 
the pro-inflammatory cytokine TNF-α gene in fibrous plaques was not significantly different 
from that in unaffected regions. The bell-shaped dependence was observed for the expression 
of the mRNA of the anti-inflammatory chemokine CCL18 gene (2.2-fold increase in expres-
sion in the initial lesions, 7.6-fold increase in fatty streaks, 9.4-fold in lipofibrous plaques, and 
5-fold increase in fibrous plaques). In all types of atherosclerotic lesions, the expression of the 
mRNA of the CCL18 gene was significantly higher than in the intact intimal.
Rather poorly expressed bell-shaped dependence was observed for the expression of the 
mRNA of the CD14 gene (the marker of monocytes migrated into intima from the blood). In 
the initial lesions, the CD14 gene expression did not increase: in fatty streaks it increased by 
2.3-fold; in lipofibrous plaques, by 1.8-fold; and in fibrous plaques, by 1.6-fold. The expres-
sion of IL-1β gene mRNA, in whole, increased steadily as the degree of atherosclerotic lesion 
increased: in the initial lesions, expression was increased by 9.6-fold; in fatty streaks, by 5.6-
fold; in lipofibrous plaques, by 10.3-fold; and in fibrous plaques, by 26.0-fold. The expression 
of the mRNA of the CASP1 gene was relatively stable in the initial lesions and fatty streaks 
and did not change significantly in comparison with the unaffected areas, but decreased in 
advanced atherosclerotic lesions: in lypofibrous plaques by 1.9-fold and in fibrous plaques 
by 2.2-fold as compared to the norm. The mRNA expression of the APAF-1 gene was rela-
tively stable in the initial lesions, fatty streaks, and lipofibrous plaques but was significantly 
decreased in fibrous plaques—by 1.6 times—as compared to the norm. There was no signifi-
cant relationship between the levels of mRNA expression of IL-1β, CASP1, and APAF-1 genes 
and the degree of atherosclerotic lesion.
6. Interaction of mitochondrial DNA mutation burden, cellular 
composition, and expression of apoptosis- and inflammation-related 
genes in atherosclerotic lesions
An analysis was made to examine the relationship between the mtDNA variability, the qualita-
tive and quantitative changes in intimal cell composition that occur in atherosclerosis, and the 
expression of apoptosis- and inflammation-related genes. The analysis used an adaptive neu-
ral network model based on artificial neural networks and the theory of neuro-fuzzy interac-
tions [17]. It was found that there are rather similar but interdependent patterns of association 
of variables with the type of atherosclerotic lesion. The pattern of the first type (the bell-
shaped relationship with the maximum for fatty lesions) combines and similarly character-
izes the mRNA expression of CAPS9, NTN1, and UNC5A apoptosis-related genes; the mRNA 
expression of the TNF-α, CCL18, and CD14 inflammation-related genes; the CDLC+/CD14+ 
cells of the hematogenic origin; the degree of heteroplasmy by mtDNA variants m.1555A>G, 
m.14846G>A, m.14459G>A, m.751delA, m.8485G>C, m.9720delT, m.10663delT, m.8404T>C, 
and m.14207delG; as well as the total mutation burden of the mitochondrial genome. The 
pattern of the second type (the increase with the maximum attributable to fibrotic lesions) 
combines and similarly characterizes the mRNA expression of the apoptosis-related gene 
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ENO1, the mRNA expression of the IL-1β inflammation-related gene, the content of CD68+ 
cells of hematogenic origin and 2A7+ pericyte-like cells, and the degree of heteroplasmy for 
mtDNA variants m.652delG, m.3256C>T, m.5178C>A, m.14160G>A, m.16086T>C, m.368A>G, 
and m.16389G>A. The pattern of the third type (reduction with a minimum occurring in the 
fibrotic type of lesion) combines and similarly characterizes the mRNA expression of the 
CAPS9 apoptosis-related gene and partly the NTN1 and UNC5A genes (the two indicators 
belong to two patterns), the mRNA expression of the inflammation-related genes CASP1 and 
APAF-1, the content of 3G5+ pericyte-like cells, and the degree of heteroplasmy for mtDNA 
variants m.13513G>A and m.12315G>A. The pattern of the fourth type (lack of interrelation 
or disordered neuro-fuzzy association of parameters with the type of lesion) combines and 
similarly characterizes the mRNA expression of the apoptosis-related gene NTN4, in part the 
mRNA expression of the CASP1 inflammation-related gene (belonging to the two patterns), 
smooth muscle actin α-positive resident cells, and the degree of heteroplasmy for mtDNA 
variants m.716T>G, m.3316G>A, m.3336C>T, m.5132delAA, m.6489C>A, m.9379G>A, 
m.9480del15, m.14482C>G, and m.14487T>C.
Thus, at least three groups of nonequilibrium interactions were identified: between the 
mtDNA mutation burden and mRNA expression of TNF-α, CCL18, and CASP9 genes; 
between cell composition and mRNA expression of TNF-α, CCL18, ENO1, and UNC5A genes; 
and between the mtDNA mutation burden and the cellular composition, in particular, the 
ratio of 2A7- and 3G5-positive cells.
7. Mitochondrial genome variability and subclinical atherosclerosis
The study of the degree of mtDNA heteroplasmy by detected atherosclerosis-related muta-
tions was performed in nonrelative women. At the first stage of the study, 183 apparently 
healthy women were screened. Study participants had no clinical manifestations of cardio-
vascular diseases, and an ultrasonographic examination of carotid arteries was performed, 
followed by a quantitative measurement of carotid intima-media thickness (cIMT). The 
participants of the study were genotyped for 37 heteroplasmic mtDNA variants. In this 
study, five mutations of the mitochondrial genome m.3256C>T, m.14709G>A, m.12315G>A, 
m.13513G>A, and m.14846G>A were in focus, and the level of heteroplasmy was associated 
with the degree of preclinical atherosclerosis. The total mutation burden of the mitochondrial 
genome assessed by these mutations accounted for 68% of the cIMT variability, while the 
combination of conventional risk factors for cardiovascular disease accounted for only 8% of 
the variability of cIMT. Data were obtained on the correlation of the degree of heteroplasmy 
in these mutations with each other, which indicated the predominantly hereditary nature of 
these mutations, as well as the existence of proatherosclerotic haplotypes of the mitochon-
drial genome [18].
Further, those women with a high mtDNA mutation burden, who were asked to participate 
in genetic screening of the maternal relatives, were selected. In total, 37 families (1 family 
of 4 generations, 27 families of 3 generations, 7 families of 2 generations) were examined. 
Monocytes were isolated from the mononuclear fraction by affinity separation using magnetic 
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CD14 affinity microparticles on LS Separation Columns (Miltenyi Biotec, Germany). 
Genotyping was carried out on heteroplasmic variants m.1555A>G, m.5178C>A, m.3256C>T, 
m.13513G>A, m.12315G>A, m.14846G>A, and m.15059G>A. The choice of mtDNA variants 
was due to their high occurrence and the level of heteroplasmy sufficient for evaluation in the 
mathematical model of inheritance of mutations. Heteroplasmy of mtDNA by selected vari-
ants was determined by qPCR. The probability of the hereditary nature of these variants was 
calculated, as well as the probability that the above variants are mutations that arise in any 
generation and may be transmitted by the maternal line with accumulation from generation 
to generation.
When analyzing the results of genotyping mtDNA samples from maternal relatives, it 
was established that the probability of hereditary nature of variant m.1555A>G approxi-
mates to 100%; m.5178C>A, 100%; m.3256C>T, 92%; m.13513G>A, 99%; m.12315G>A, 99%; 
m.14846G>A, 100%; and m.15059G>A, 96%. The probability that the above variants may be 
somatic arising in any generation, for variant m.1555A>G accounted for 8%; m.5178C>A, for 
5%; m.3256C>T, for 19%; m.13513G>A, for 10%; m.12315G>A, for 12%; m.14846G>A, for 4%; 
and m.15059G>A, for 11%. Thus, the prevalent variants of the mitochondrial genome are 
thought to be heritable with a high degree of probability.
The differences in the degree of mtDNA heteroplasmy in various types of blood cells (mono-
cytes, neutrophils, lymphocytes, platelets, and the total fraction of leukocytes) obtained from 
non-related individuals were studied. Seventy-one study participants (32 men, 39 women) 
were examined. The leukocyte fraction of cells was obtained from the whole citrated blood 
by gradient centrifugation using Ficoll-Paque (GE Healthcare Life Sciences, UK). Blood 
cells of various types were isolated from the leukocyte fraction by affinity separation using 
magnetic affinity microparticles on LS Separation Columns (Miltenyi Biotec, Germany). 
Heteroplasmy of mitochondrial genome was determined by pyrosequencing of short-chain 
mtDNA fragments by mtDNA variants m.13513G>A, m.3256C>T, m.3336T>C, m.12315G>A, 
and m.1555A>G. There were no significant differences in the level of heteroplasmy of these 
mutations studied between different types of blood cells from the same participant within 
the study. The only statistically significant difference was observed between neutrophils and 
lymphocytes by mutation m.1555A>G. The obtained data indicate that these mutations are 
not accumulated during differentiation of blood cells, but more probably are inherent in the 
progenitor cells in the bone marrow. Thus, for the studies of single nucleotide substitutions of 
mtDNA in various pathologies, it is possible to use whole fraction of white blood cells rather 
than certain types of them [19].
Further, the variability of mtDNA from blood leukocytes was evaluated by NGS (Roche 454 GS 
Junior Titanium platform) in a sample of 80 non-related study participants (37 healthy individ-
uals and 43 patients with subclinical carotid atherosclerosis, the diagnosis being established 
by ultrasound scanning of the common carotid arteries and measurement of cIMT). Arterial 
hypertension, diabetes mellitus, and myocardial infarction were criteria of exclusion in sam-
ple formation. Despite of the relatively low percentage of mapped readings during sequenc-
ing, the mean 70-fold mitochondrial genome coverage was provided sufficiently to detect 
single nucleotide substitutions. The possibility of sequencing using Roche 454 technology 
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made it possible to determine as accurately as possible the haplogroup of the mitochondrial 
genome, considering all single nucleotide substitutions throughout the mtDNA. As a result, 
mitochondrial haplogroups H, U, T, and J were the most common (85.7% of cases), which 
corresponds to general data from the Russian population. Haplogroups I, W, R, and D were 
represented only among persons with preclinical atherosclerosis. In turn, haplogroups N, V, 
and M were found only among apparently healthy individuals. When calculating the odds 
ratio for preclinical atherosclerosis, it was established that belonging to haplogroup H is asso-
ciated with an increased risk of atherosclerosis (χ2 = 3.97, p = 0.046, OR = 2.76, 95% confidence 
interval 1.01–7.58). Belonging to haplogroups T and U was associated with reduced risk of 
subclinical carotid atherosclerosis (OR = 0.31 and OR = 0.57, respectively). The increased risk 
of atherosclerosis and its clinical manifestations (e.g., myocardial infarction) in representa-
tives of haplogroup H may be associated with the differences in the functional activity of 
mitochondria [20, 21].
According to the data of whole mtDNA sequencing, the list of variants of the mitochondrial 
genome presumably determining the individual genetic predisposition to atherosclerosis was 
compiled. The methodology used to assess the variability of the mitochondrial genome as 
a marker of predisposition to atherosclerosis involved the use of data on the presence of 12 
mtDNA variants and considered the calculation of the cumulative mutation burden for those 
mtDNA variants.
The ROC analysis was performed to assess the diagnostic effectiveness of this method for 
estimating the total mutation burden of mtDNA to determine the predisposition to athero-
sclerosis. The following results were obtained: the area under the curve was 0.791, sensitiv-
ity of the test was 73.3%, and specificity of the test was 75.0%. The accuracy of the method 
was 74.0%, the proportion of true positive results was 42.9%, and the proportion of true 
negative results was 31.1%. The odds ratio for the risk of atherosclerosis was 8.25 (95% con-
fidence interval 2.9–23.29), and the relative risk was 2.41. The relationship between mtDNA 
variants and their combinations with atherosclerosis, conventional risk factors for cardio-
vascular diseases, and age-gender variation was characterized. There were no significant 
differences between the mean values of blood lipids, both between persons belonging to 
different haplogroups and between groups with the presence and absence of preclinical ath-
erosclerosis. Nevertheless, the mean value of low-density lipoprotein (LDL) to high-density 
lipoprotein (HDL) ratio in the group of patients with preclinical atherosclerosis was slightly 
increased in comparison with healthy subjects (3.0 ± 1.7 versus 2.7 ± 1.1, p < 0.05). There was 
no correlation between mtDNA variants and their combinations with conventional cardio-
vascular risk factors and age-gender variation (Sobenin et al., not published).
8. Mitochondrial DNA mutation burden and functional activity of cells
Based on the results of whole genome sequencing and pyrosequencing of mtDNA from 
normal and atherosclerotic sites of intima of the aorta, as well as of genotyping of mtDNA 
from the blood cells of the above study participants, valuable information was obtained on 
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proatherosclerotic mtDNA variants (m.652delG, m.3256C>T, m12315G>A, m.14459G>A, 
m.15059G>A, m.368A>G, m.751delA, m.8404T>C, m.8485G>C, m.9720delT, m.14160G>A, 
m.14207delG, M.16086T>C, and m.16389G>A) and antiatherosclerotic mtDNA vari-
ants (m.1555A>G, m.5178C>A, m.13513G>A, and m.14846G>A). These data were used to 
determine whether the study participants belonged to persons with a low, neutral, or high 
mtDNA mutation burden, as judged by combinations of the proatherosclerotic or antiath-
erosclerotic alleles of mtDNA variants, or the highest possible matching to Cambridge refer-
ence sequence of the mitochondrial human genome, version NC_012920.1. Of the examined 
and genotyped persons (a total of 525 subjects), 139 (26.5%) met the above criteria. Of these, 
97 subjects signed informed consent and donated venous blood for the study of functional 
activity of blood monocytes. Among them, 32 were included in the group with a low mtDNA 
mutation burden; 29, in the group with a neutral mtDNA genotype; and 36, in the group 
with a high mtDNA mutation burden (Sobenin, personal communication).
It is known that atherosclerotic phenotype at the cellular level for cells actively involved in 
the formation of atherosclerotic lesions is characterized by increased proliferative activity, 
increased protein and connective tissue matrix synthesis, and accumulation of esterified cho-
lesterol. Recently, the markers of cell activation by pro-inflammatory (M1) and anti-inflam-
matory (M2) types, reflecting the processes of chronic inflammation in atherogenesis, have 
been added to phenotype description.
Mononuclear cells were isolated from the leukocyte fraction by affinity separation using magnetic 
CD14 affinity microparticles on LS Separation Columns (Miltenyi Biotec, Germany) and cultured 
in serum-free X-Vivo 10 medium (Lonza). To stimulate cell activation into pro-inflammatory 
phenotype, interferon-gamma was added to the medium at a final concentration of 100 ng/ml 
(1-day incubation). To stimulate cell activation into anti-inflammatory phenotype, interleukin-4 
was added to the medium at a final concentration of 10 ng/ml (6-days incubation). After incuba-
tion, concentrations of TNF-α (the marker of activation into pro-inflammatory phenotype) and 
chemokine CCL18 (the marker of activation into anti-inflammatory phenotype) were measured 
in culture medium by enzyme-linked immunosorbent assay (ELISA) technique. To measure the 
expression of TNF-α and CCL18 genes, mRNA was extracted from cells. To determine the ability 
of cells to accumulate cholesterol, the cells were incubated in the presence of modified low-density 
lipoprotein (LDL) (100 μg/ml culture medium) obtained from the blood of patients with 
coronary heart disease by gradient ultracentrifugation followed by isolation of the fraction 
of modified lipoproteins by affinity chromatography on ricin-agglutinin Sepharose (Sigma, 
USA). To determine proliferative activity, the cultured cells were incubated for 24 h in the 
presence of 10 μCi/ml of [3H]-thymidine. To determine the synthetic activity, the cells were 
incubated for 24 h in the presence of 10 μCi/ml [14C]-leucine. To determine the synthesis of 
the connective tissue matrix components (collagen), the cells were incubated for 24 h in the 
presence of 5 μCi/ml [3H]-proline. The measurement of the respiration rate of mitochondria 
was carried out by oximetry; the coefficient of respiratory control and the phosphorylation 
coefficient characterizing the rate of ATP synthesis were determined. The determination of 
the rate of oxygen uptake by cells was carried out with Clarke oxygen electrode on Oxygraph 
Plus System instrument (Hansatech Instruments, UK); 2,4-dinitrophenol (0.2 mM) blocking 
the synthesis of adenosine triphosphate (ADP) was used as an uncoupler of oxidative 
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phosphorylation. The measurement of endogenous respiration of cells was carried out on intact 
non-permeabilized cells and provided an overall assessment of cell respiration using endog-
enous substrates.
Significant differences were found between the cells for such parameters as proliferative 
activity, synthetic activity, synthesis of matrix components (collagen), the ability of cells to 
accumulate cholesterol from modified low-density lipoproteins, stimulated secretion of anti-
inflammatory chemokine CCL18, TNF-α gene expression, CCL18 gene expression, and mito-
chondrial dysfunction markers (respiratory control and phosphorylation coefficients, oxygen 
consumption rate). At the same time, the cells did not differ significantly in the basal secretion 
of TNF-α and CCL18, as well as in the stimulated secretion of TNF-α (Sobenin, personal com-
munication). The data were analyzed using an adaptive neural network model to identify the 
relationship between mtDNA damage and functional impairment of cells. It was necessary 
to consider the ambiguity of the results obtained, which was due to the complexity of com-
binations of phenotypic traits, to high individual variability of cellular properties from dif-
ferent donors, and to far-reaching individual combinations of mtDNA variants, which were 
employed to classify the cells by the degree of the mtDNA mutation burden. The considered 
mtDNA variants were in the loci belonging to the hypervariable segments 1 and 2; loci respon-
sible for the coding of the 12S and 16S subunits of ribosomal RNA; leucine tRNA; subunits 
2, 4, 5, and 6 of NADH dehydrogenase; subunits I and III of cytochrome C oxidase; subunit 
8 ATP synthetase F0; cytochrome b; as well as a membrane-bound site. Thus, the analysis 
belonged to a class of fuzzy, poorly formalized problems and was carried out using the theory 
of fuzzy sets and neuro-fuzzy approaches that potentially can analyze the nonequilibrium 
interaction of many genotypic and phenotypic characteristics.
The cells with a low and neutral mtDNA mutation burden did not differ significantly by pro-
liferative and synthetic activity. The cells with a high mtDNA mutation burden were charac-
terized by 1.8-fold increased proliferative activity (p < 0.001) and 1.4-fold increased synthetic 
activity (p < 0.001). However, in analyzing the synthesis of collagen (the main protein compo-
nent of the connective tissue matrix), it turned out that in cells with a high mtDNA mutation 
burden, matrix synthesis was significantly decreased both in comparison with the cells with a 
neutral mtDNA mutation burden (by 1.3-fold) and cells with a low mtDNA mutation burden 
(by 1.1-fold) (p = 0.022) (Sobenin, not published).
The ability of cells to accumulate cholesterol from modified low-density lipoprotein was the 
highest in cells with a high mtDNA mutation burden; the intracellular cholesterol content 
increased by 1.7-fold in comparison with control cells, p < 0.001. At the same time, the cells 
with a low or neutral mtDNA mutation burden poorly accumulated cholesterol; in some 
cases, there was no significant increase of cholesterol level in cells, and if the accumulation 
of cholesterol occurred, it was rather moderate (by 1.15- to 1.35-fold). The accumulation of 
cholesterol correlated with the mtDNA mutation burden (r = 0.721, p < 0.001) and proliferative 
activity of cells (r = 0.483, p < 0.001), but not with synthetic activity. Proliferative activity did 
not correlate with synthetic activity.
Thus, by traditional cellular markers of atherosclerosis (fibrosis, proliferation, lipidosis), the cells 
with a high mtDNA mutation burden typically demonstrated proatherosclerotic phenotype, 
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except for the dissonance with respect to collagen synthesis (Sobenin, not published). On the 
one hand, monocytes-macrophages are not professional producers of matrix in tissues, but 
on the other hand, this dissonance may reflect the dysregulation of cell adaptation, possibly 
related specifically to the presence of a high mtDNA mutation burden. Indirect confirmation 
of the latter assumption may be the characteristics of cell activation by an anti-inflammatory 
or pro-inflammatory phenotype.
The cells did not differ significantly by basal secretion of TNF-α (the marker of pro-inflam-
matory type of activation); there was a tendency to decrease of basal TNF-α secretion in the 
row “low-neutral-high mtDNA mutation burden,” which did not reach statistical significance 
(p = 0.19). Stimulated by interferon-gamma secretion of TNF-α also did not differ significantly; 
there was a tendency to decrease of stimulated TNF-α secretion in the row “low-neutral-high 
mtDNA mutation burden,” which also did not reach statistical significance (p = 0.18). The 
degree of stimulation of the secretion of TNF-α (the ratio of stimulated secretion to basal) 
was the same in all types of cells. Stimulated secretion of TNF-α negatively correlated with 
proliferative activity (r = −0.235; p = 0.021).
Basal secretion of CCL18 (the marker of anti-inflammatory type of activation) was practically 
absent, which is normal, as the cells usually do not secrete CCL18 in the absence of stimula-
tion. The cells with a neutral mtDNA mutation burden were the best responders to stimula-
tion with interleukin-4 (p = 0.038), while the cells with a low or high mtDNA mutation burden 
poorly responded to stimulation and did not differ in the extent of response. The stimulated 
secretion of CCL18 did not correlate with any of other cellular markers of atherosclerosis.
Ambiguous dissonance was observed not only at the level of expression of the product but 
also at the level of expression of the coding genes. The expression of the TNF-α gene was the 
highest in cells with a high mtDNA mutation burden, and the lowest in cells with a neutral 
mtDNA mutation burden, and did not correlate with either the degree of mtDNA mutation 
burden or the basal or stimulated TNF-α secretion. In contrast, the expression of CCL18 gene 
significantly increased in the row “low-neutral-high mtDNA mutation burden” and corre-
lated with the degree of mtDNA mutation burden (r = 0.782, p < 0.001), but not with stimu-
lated CCL18 secretion.
Among the remaining characteristics, the expression of the TNF-α gene correlated only with 
the accumulation of cholesterol in the cells (r = 0.347, p < 0.001). CCL18 gene expression nega-
tively correlated with stimulated secretion of TNF-α (r = −0.211, p = 0.038), and synthesis of 
matrix components (r = −0.201; p = 0.048) positively correlated with proliferative activity of 
cells (r = 0.486; p < 0.001) and the accumulation of cholesterol caused by modified low-density 
lipoproteins (r = 0.487; p < 0.001).
Obviously, such combinations of phenotypic cellular markers of atherosclerosis and mtDNA 
mutation burden should be associated with mitochondrial dysfunction. Indeed, such a dysfunc-
tion was detected, and it was increasing in the row “low-neutral-high mtDNA mutation bur-
den,” by manifesting the decrease of the coefficient of respiratory control, the phosphorylation 
coefficient, and the rate of oxygen consumption. Correlation coefficients between these indices 
were r = −0.692 (p < 0.001), r = −0.934 (p < 0.001), and r = −0.697 (p < 0.001), respectively. The rate 
of oxygen uptake in cultured cells with a low mtDNA mutation burden when inhibited by an 
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uncoupler of oxidative phosphorylation decreased significantly slower than in cells with neutral 
or high mtDNA mutation burden. Such results of mitochondrial dysfunction assessment were 
quite predictable, since the studied mutations of the mitochondrial genome should influence 
the efficiency of oxidative phosphorylation in the mitochondria by the nature of mutations. It 
should be noted that the parameters of mitochondrial dysfunction were associated with sev-
eral phenotypic cellular markers of atherosclerosis. Thus, the coefficient of respiratory control 
negatively correlated with the proliferative activity of cells (r = −0.461, p < 0.001), the synthetic 
activity of cells (r = −0.222; p = 0.029), the accumulation of intracellular cholesterol (r = −0.489; 
p < 0.001), and the expression of the CCL18 gene (r = −0.453, p < 0.001) and positively correlated 
with stimulated secretion of TNF-α (r = 0.253, p = 0.012). There was a positive correlation with 
both the phosphorylation coefficient (r = 0.607, p < 0.001) and the rate of oxygen consumption 
(r = 0.513, p < 0.001). The phosphorylation coefficient negatively correlated with proliferative 
activity of cells (r = −0.645, p < 0.001), the synthetic activity of cells (r = −0.352, p < 0.001), the 
accumulation of intracellular cholesterol (r = −0.678, p < 0.001), and the CCL18 gene expression 
(r = −0.615, p < 0.001) and positively correlated with the rate of oxygen consumption (r = 0.668; 
p < 0.001). Finally, the oxygen absorption rate negatively correlated with the proliferative activ-
ity of cells (r = −0.450, p < 0.001), the synthetic activity of cells (r = −0.396, p < 0.001), the accu-
mulation of intracellular cholesterol (r = −0.535; p < 0.001), and the expression of CCL18 gene 
(r = −0.457, p < 0.001) (Sobenin et al., not published).
In the analysis of the relationship between mtDNA damage and functional impairment of cells 
with the use of an adaptive neural network model, the similar and interdependent patterns of 
relationships were identified (Sobenin et al., not published). The pattern of type 1 is compliant 
to the typical atherosclerotic phenotype (increased proliferation, increased synthetic activity, 
the ability of cells to accumulate cholesterol, the unchanged expression of TNF-α and CCL18 
genes, high cell activation both into pro-inflammatory and anti-inflammatory phenotypes, 
and evident mitochondrial dysfunction). This pattern is characterized by the presence of com-
binations of homoplasmic mtDNA variants m.930G, m.7028C, and m.11251A and heteroplas-
mic mtDNA variants m.652delG, m.751delA, m.3256C>T, m.12315G>A, and m.14459G>A. 
The pattern of type 2 represents an atypical atherosclerotic phenotype (increased prolif-
eration without increased synthetic activity, the ability of cells to accumulate cholesterol, 
increased expression of TNF-α and CCL18 genes, low cell activation into pro-inflammatory 
phenotype, high cell activation into anti-inflammatory phenotype, and evident mitochon-
drial dysfunction). This pattern is characterized by the presence of combinations of homo-
plasmic mtDNA variants m.73A, m.930G, and m.16296C and heteroplasmic mtDNA variants 
m.368A>G, m.652delG, m.3256C>T, m.8404T>C, m.8485G>C, m.12315G>A, m.14160G>A, 
and m.15059G>A. Finally, the pattern of type 3 represents normal (non-atherosclerotic) phe-
notype (low proliferative activity, low synthetic activity, low ability of cells to accumulate 
cholesterol, unchanged expression of TNF-α and CCL18 genes, moderate equilibrium cell 
activation both into pro-inflammatory and anti-inflammatory phenotypes, and the absence 
of manifestations of mitochondrial dysfunction). This pattern is characterized by the pres-
ence of combinations of homoplasmic mtDNA variants m.5460A, m.11719G, m.14233A, and 
m.14766C and heteroplasmic mtDNA variants m.1555A>G, m.5178C>A, and m.14846G>A; 
however, in this pattern proatherosclerotic heteroplasmic mtDNA variants m.652delG and 
m.3256C>T nonrandomly occur.




The data obtained from the described studies allow to analyze the relationship of mtDNA 
damage and its variability; qualitative and quantitative changes in the cellular composition 
of arterial intima, occurring in atherosclerosis; as well as expression of apoptosis- and inflam-
mation-related genes. In maternal relatives in 2–4 generations, the differences in the degree 
of mtDNA heteroplasmy in different types of blood cells obtained from the same individu-
als helped to identify heritable mutations accumulated in the cells, and somatic mutations 
arising during the life of the individual. The relationship of mtDNA variants with athero-
sclerosis, traditional risk factors for cardiovascular disease, and age-gender variation was 
identified and characterized. In cell culture studies, the relationship of individual mtDNA 
mutation burden with functional activity of cells was studied. Taken together, the results of 
these studies strongly support the hypothesis on proatherosclerotic role of mtDNA mutations 
in atherogenesis.
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